283 related articles for article (PubMed ID: 27608310)
1. [Approach to directed therapy after knowledge of the isolate: carbapenemase-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii].
Martínez JA
Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():31-4. PubMed ID: 27608310
[TBL] [Abstract][Full Text] [Related]
2. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
3. Rapid Blue-Carba test: reduction in the detection time of carbapenemases performed from a 4-hour bacterial lawn.
Nastro M; Ayora M; García S; Vay C; Famiglietti Á; Rodriguez CH
J Chemother; 2017 Jun; 29(3):150-153. PubMed ID: 27347714
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
Dias VC; Resende JA; Bastos AN; De Andrade Bastos LQ; De Andrade Bastos VQ; Bastos RV; Diniz CG; Da Silva VL
Microb Drug Resist; 2017 Oct; 23(7):852-863. PubMed ID: 28437232
[TBL] [Abstract][Full Text] [Related]
5. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
6. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multidrug-resistant Gram-negative infections in children.
Hsu AJ; Tamma PD
Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
[TBL] [Abstract][Full Text] [Related]
8. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections.
Kunz AN; Brook I
Chemotherapy; 2010; 56(6):492-500. PubMed ID: 21099222
[TBL] [Abstract][Full Text] [Related]
9. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.
Zavascki AP; Carvalhaes CG; Picão RC; Gales AC
Expert Rev Anti Infect Ther; 2010 Jan; 8(1):71-93. PubMed ID: 20014903
[TBL] [Abstract][Full Text] [Related]
10. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
Shanthi M; Sekar U
J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
[TBL] [Abstract][Full Text] [Related]
11. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
[No Abstract] [Full Text] [Related]
12. Associations between carbapenem use, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii.
Apisarnthanarak A; Jitpokasem S; Mundy LM
Infect Control Hosp Epidemiol; 2013 Nov; 34(11):1235-7. PubMed ID: 24113616
[No Abstract] [Full Text] [Related]
13. Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?
Tamma PD; Wang R; Lewis S; Opene BNA; Simner PJ
Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1378-1379. PubMed ID: 28965496
[No Abstract] [Full Text] [Related]
14. [Laboratory detection of carbapenemase-producing Enterobacteriaceae].
Cercenado E
Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():8-11. PubMed ID: 26365726
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of carbapenemase production among gram-negative bacteria in saudi arabia.
Memish ZA; Assiri A; Almasri M; Roshdy H; Hathout H; Kaase M; Gatermann SG; Yezli S
Microb Drug Resist; 2015 Jun; 21(3):307-14. PubMed ID: 25569024
[TBL] [Abstract][Full Text] [Related]
16. The role of antimicrobial stewardship in curbing carbapenem resistance.
Bogan C; Marchaim D
Future Microbiol; 2013 Aug; 8(8):979-91. PubMed ID: 23902145
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
18. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
Stock I
Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
[TBL] [Abstract][Full Text] [Related]
19. "Future" threat of gram-negative resistance in Singapore.
Tan TT
Ann Acad Med Singap; 2008 Oct; 37(10):884-90. PubMed ID: 19037523
[TBL] [Abstract][Full Text] [Related]
20. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.
Poirel L; Nordmann P
Clin Microbiol Infect; 2006 Sep; 12(9):826-36. PubMed ID: 16882287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
